研究单位：[1]Sun Yat-sen University[2]Peking University Third Hospital,Beijing,China[3]Sichuan Cancer Hospital,Chengdu,China[4]Fujian Province Cancer Hospital,Fuzhou,China[5]Guizhou Cancer Hospital,Guiyang,China[6]Zhejiang Cancer Hospital,Hangzhou,China[7]Jiangxi Cancer Hospital,Nanchang,China[8]The First Affiliated Hospital of Guangxi Medical University,Nanning,China[9]Fudan University Shanghai Cancer Center,Shanghai,China[10]Zhongnan Hospital of Wuhan University,Wuhan,China[11]Xijing Hospital,Xi'an,China[12]The First Affiliated Hospital of Xiamen University,Xiamen,China
This is a multicenter, randomized controlled, phase III clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of PD-1 antibody with chemoradiotherapy versus chemoradiotherapy alone in recurrent nasopharyngeal carcinoma patients.
